Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Set To Expand To $8.66 Billion By 2030 At 4.3% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market In 2026, And How Will Its Value Evolve By 2030?
The market size for rapid tests based on lateral flow immunoassay (LFIA) has demonstrated consistent expansion in recent years. This market is anticipated to increase from $7.17 billion in 2025 to $7.31 billion in 2026, driven by a compound annual growth rate (CAGR) of 2.0%. Key contributors to its historical growth include the wider implementation of rapid infectious disease screening, the growing preference for pregnancy and fertility tests, advancements in point-of-care diagnostics, the presence of affordable rapid tests, and escalating public health screening initiatives.
The market for lateral flow immunoassay (lfia) based rapid tests is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach a valuation of $8.67 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. This projected growth is driven by factors such as greater investments in decentralized diagnostics, the broadened use of self-testing applications, a heightened need for swift cardiac and toxicology screenings, increasing integration with digital health platforms, and an elevated emphasis on detecting diseases early. Key trends anticipated during this period encompass a surging demand for rapid immunoassay-based testing, the increasing uptake of home-use lfia kits, expanded application of multiplex detection assays, a wider scope for infectious disease testing, and a stronger emphasis on designing user-friendly tests.
Access Your Free Sample Report For In-Depth Market Analysis:
What Leading Drivers Are Supporting The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Expansion?
The escalating occurrence of chronic illnesses is anticipated to fuel expansion in the lateral flow immunoassay (LFIA) based rapid test market moving forward. Chronic conditions, also termed non-communicable diseases (NCDs), are enduring health issues lasting for prolonged durations, frequently for an individual’s entire life. Lateral flow immunoassay (LFIA) based rapid tests facilitate early diagnosis, on-site testing, quick outcomes, consistent oversight, and diminish healthcare expenditures associated with managing chronic ailments. These LFIA-based rapid tests are highly regarded in handling chronic diseases as they provide swift and accessible results, empowering patients and medical practitioners to make timely choices regarding therapies and dietary modifications. As an illustration, data from June 2024 by the National Health Service, a UK government entity, revealed that 3,615,330 persons registered with a general practitioner (GP) were identified with non-diabetic hyperglycemia or pre-diabetes (a state of elevated blood sugar not severe enough to be classified as diabetes) in 2023. This represented an 18% increase from 3,065,825 instances recorded in 2022. Consequently, the rising incidence of chronic diseases is propelling the growth of the lateral flow immunoassay (LFIA) based rapid test market.
How Is Segmentation Applied In The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Segment Analysis?
The lateral flow immunoassay (lfia) based rapid test market covered in this report is segmented –
1) By Technique: Competitive Assay, Sandwich Assay, Multiplex Detection Assay
2) By Application: Infectious Disease, Pregnancy And Fertility, Toxicology, Cardiac Marker And Cholesterol Testing, Other Applications
3) By End-Users: Hospitals And Clinics, Diagnostic Laboratories, Home Care, Other End Users
Subsegments:
1) By Competitive Assay: Direct Competitive Assays, Indirect Competitive Assays
2) By Sandwich Assay: Single-step Sandwich Assays, Two-step Sandwich Assays
3) By Multiplex Detection Assay: Multi-analyte Assays, Simultaneous Detection Of Various Targets
What Emerging Trends Are Seen In The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
Leading companies within the lateral flow immunoassay (LFIA)-based rapid test market are prioritizing technologies such as Integrated Health Solutions to improve diagnostic efficiency, streamline operational workflows, and offer comprehensive patient care by facilitating better data exchange and collaboration across healthcare platforms. Integrated Health Solutions are defined as extensive healthcare systems that interlink various services, technologies, and data to enhance patient care and optimize operations. As an illustration, in June 2024, F. Hoffmann-La Roche AG, a pharmaceutical company based in Switzerland, launched the analytical units for its Cobas Pro integrated solutions. The Cobas Pro system can handle up to 1,000 samples per hour with its sample supply unit and includes high-speed analytical units capable of performing up to 900 tests per hour for the ISE (ion-selective electrode) and 1,000 tests per hour for the Cobas C 503 unit, which specializes in clinical chemistry.
Who Are The Companies Participating In The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Environment?
Major companies operating in the lateral flow immunoassay (lfia) based rapid test market are Abbott Laboratories, F. Hoffmann-La Roche, Quidel Corporation, Becton Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., PerkinElmer Inc., Hologic Inc., LTEK Co. Ltd., JOYSBIO Biotechnology, Jiangsu Medomics Medical Technologies, Diagnocure, Ubio Biotechnology Systems, Elabscience® Immunoassay Kits, FyoniBio / Glycotope GmbH, Atomo Diagnostics Limited, INDICAL Bioscience, Lionex Gmbh, BIOMED Labordiagnostik GmbH, EKF Diagnostics, Launch Diagnostics, Diagnostic Instruments Ltd, Qiagen N.V., Merck KGaA, 3a Diagnostics, Roche Holding AG, Biomaxima, SensDx, Vitrosens Biotechnology, Bioeasy Biotechnology, Fujirebio, Immunodiagnostic Systems Holdings PLC, Mesa Biotech Inc, CTK Biotech
Get The Full Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Report:
Which Region Leads The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market In Terms Of Market Share?
North America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lateral flow immunoassay (lfia) based rapid test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Market 2026, By The Business Research Company
Lateral Flow Assays Market Report 2026
https://www.thebusinessresearchcompany.com/report/lateral-flow-assays-global-market-report
Immunoassay Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report
Immunodiagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunodiagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
